LymphedemaV1, PascalFrancis, Corpus, bibRecord, 000423

Erysipelas and lymphedema

Identifieur interne : 000423 ( PascalFrancis/Corpus ); précédent : 000422; suivant : 000424

Erysipelas and lymphedema

Auteurs : Loïc Vaillant

Source :

Phlebolymphology [ 1286-0107 ] ; 2007.

RBID : Pascal:08-0028056

Descripteurs français

Pascal (Inist)
- Cellulite, Lymphoedème, Maladie héréditaire, Bactériose, Streptococcie, Erysipèle, Acquis, Congénital, Enfant, Diosmine, Glande mammaire, Circulation lymphatique, Complication, Chronique, Fièvre, Lymphe, Traitement, Antibiotique, Prévention, Facteur risque, Physiothérapie, Plaie, Veinotrope.

English descriptors

KwdEn :
- Acquired, Antibiotic, Bacteriosis, Cellulitis, Child, Chronic, Complication, Congenital, Diosmin, Erysipelas, Fever, Genetic disease, Lymph, Lymphatic circulation, Lymphedema, Mammary gland, Physiotherapy, Prevention, Risk factor, Streptococcal infection, Treatment, Venotropic agent, Wound.

Abstract

Erysipelas is a nonnecrotizing bacterial hypodermal cellulitis usually associated with streptococcal infection. It may be a mainly secondary complication of chronic lymphedema, and occurs in 20% to 30% of cases. The first presenting signs are sudden fever and shivering. The clinical feature is inflammatory plaque, which is often chronic and accompanied by fever. Inflammatory plaque is promoted by lymph stasis, and is marked by inflammatory episodes that often regress spontaneously. Erysipelas per se is mainly treated with antibiotics, and adjuvant therapies are not justified. The prevention of recurrence is primary. Since lymphedema is the first risk factor for recurrence, its treatment and risk of occurrence must be considered. This includes physiotherapy, well-adapted compression therapy, and avoidance of wounds.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1286-0107`
A05				`@2 14`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Erysipelas and lymphedema`
A11	`01`	`1`		`@1 VAILLANT (Loïc)`
A14	`01`			`@1 Université François Rabelais @2 Tours @3 FRA @Z 1 aut.`
A20				`@1 120-124`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 27793 @5 354000162422740030`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 19 ref.`
A47	`01`	`1`		`@0 08-0028056`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Phlebolymphology`
A66	`01`			`@0 FRA`
C01	`01`		`ENG`	@0 Erysipelas is a nonnecrotizing bacterial hypodermal cellulitis usually associated with streptococcal infection. It may be a mainly secondary complication of chronic lymphedema, and occurs in 20% to 30% of cases. The first presenting signs are sudden fever and shivering. The clinical feature is inflammatory plaque, which is often chronic and accompanied by fever. Inflammatory plaque is promoted by lymph stasis, and is marked by inflammatory episodes that often regress spontaneously. Erysipelas per se is mainly treated with antibiotics, and adjuvant therapies are not justified. The prevention of recurrence is primary. Since lymphedema is the first risk factor for recurrence, its treatment and risk of occurrence must be considered. This includes physiotherapy, well-adapted compression therapy, and avoidance of wounds.
C02	`01`	`X`		`@0 002B24B04`
C02	`02`	`X`		`@0 002B02F07`
C02	`03`	`X`		`@0 002B12B01`
C03	`01`	`X`	`FRE`	`@0 Cellulite @5 01`
C03	`01`	`X`	`ENG`	`@0 Cellulitis @5 01`
C03	`01`	`X`	`SPA`	`@0 Celulitis @5 01`
C03	`02`	`X`	`FRE`	`@0 Lymphoedème @5 02`
C03	`02`	`X`	`ENG`	`@0 Lymphedema @5 02`
C03	`02`	`X`	`SPA`	`@0 Linfedema @5 02`
C03	`03`	`X`	`FRE`	`@0 Maladie héréditaire @5 03`
C03	`03`	`X`	`ENG`	`@0 Genetic disease @5 03`
C03	`03`	`X`	`SPA`	`@0 Enfermedad hereditaria @5 03`
C03	`04`	`X`	`FRE`	`@0 Bactériose @5 04`
C03	`04`	`X`	`ENG`	`@0 Bacteriosis @5 04`
C03	`04`	`X`	`SPA`	`@0 Bacteriosis @5 04`
C03	`05`	`X`	`FRE`	`@0 Streptococcie @5 05`
C03	`05`	`X`	`ENG`	`@0 Streptococcal infection @5 05`
C03	`05`	`X`	`SPA`	`@0 Estreptococia @5 05`
C03	`06`	`X`	`FRE`	`@0 Erysipèle @5 09`
C03	`06`	`X`	`ENG`	`@0 Erysipelas @5 09`
C03	`06`	`X`	`SPA`	`@0 Erisipela @5 09`
C03	`07`	`X`	`FRE`	`@0 Acquis @5 10`
C03	`07`	`X`	`ENG`	`@0 Acquired @5 10`
C03	`07`	`X`	`SPA`	`@0 Adquirido @5 10`
C03	`08`	`X`	`FRE`	`@0 Congénital @5 11`
C03	`08`	`X`	`ENG`	`@0 Congenital @5 11`
C03	`08`	`X`	`SPA`	`@0 Congénito @5 11`
C03	`09`	`X`	`FRE`	`@0 Enfant @5 12`
C03	`09`	`X`	`ENG`	`@0 Child @5 12`
C03	`09`	`X`	`SPA`	`@0 Niño @5 12`
C03	`10`	`X`	`FRE`	`@0 Diosmine @2 NK @2 FR @5 13`
C03	`10`	`X`	`ENG`	`@0 Diosmin @2 NK @2 FR @5 13`
C03	`10`	`X`	`SPA`	`@0 Diosmina @2 NK @2 FR @5 13`
C03	`11`	`X`	`FRE`	`@0 Glande mammaire @5 14`
C03	`11`	`X`	`ENG`	`@0 Mammary gland @5 14`
C03	`11`	`X`	`SPA`	`@0 Glándula mamaria @5 14`
C03	`12`	`X`	`FRE`	`@0 Circulation lymphatique @5 15`
C03	`12`	`X`	`ENG`	`@0 Lymphatic circulation @5 15`
C03	`12`	`X`	`SPA`	`@0 Circulación linfática @5 15`
C03	`13`	`X`	`FRE`	`@0 Complication @5 16`
C03	`13`	`X`	`ENG`	`@0 Complication @5 16`
C03	`13`	`X`	`SPA`	`@0 Complicación @5 16`
C03	`14`	`X`	`FRE`	`@0 Chronique @5 17`
C03	`14`	`X`	`ENG`	`@0 Chronic @5 17`
C03	`14`	`X`	`SPA`	`@0 Crónico @5 17`
C03	`15`	`X`	`FRE`	`@0 Fièvre @5 19`
C03	`15`	`X`	`ENG`	`@0 Fever @5 19`
C03	`15`	`X`	`SPA`	`@0 Fiebre @5 19`
C03	`16`	`X`	`FRE`	`@0 Lymphe @5 20`
C03	`16`	`X`	`ENG`	`@0 Lymph @5 20`
C03	`16`	`X`	`SPA`	`@0 Linfa @5 20`
C03	`17`	`X`	`FRE`	`@0 Traitement @5 21`
C03	`17`	`X`	`ENG`	`@0 Treatment @5 21`
C03	`17`	`X`	`SPA`	`@0 Tratamiento @5 21`
C03	`18`	`X`	`FRE`	`@0 Antibiotique @5 22`
C03	`18`	`X`	`ENG`	`@0 Antibiotic @5 22`
C03	`18`	`X`	`SPA`	`@0 Antibiótico @5 22`
C03	`19`	`X`	`FRE`	`@0 Prévention @5 23`
C03	`19`	`X`	`ENG`	`@0 Prevention @5 23`
C03	`19`	`X`	`SPA`	`@0 Prevención @5 23`
C03	`20`	`X`	`FRE`	`@0 Facteur risque @5 24`
C03	`20`	`X`	`ENG`	`@0 Risk factor @5 24`
C03	`20`	`X`	`SPA`	`@0 Factor riesgo @5 24`
C03	`21`	`X`	`FRE`	`@0 Physiothérapie @5 25`
C03	`21`	`X`	`ENG`	`@0 Physiotherapy @5 25`
C03	`21`	`X`	`SPA`	`@0 Fisioterapia @5 25`
C03	`22`	`X`	`FRE`	`@0 Plaie @5 26`
C03	`22`	`X`	`ENG`	`@0 Wound @5 26`
C03	`22`	`X`	`SPA`	`@0 Herida @5 26`
C03	`23`	`X`	`FRE`	`@0 Veinotrope @5 78`
C03	`23`	`X`	`ENG`	`@0 Venotropic agent @5 78`
C03	`23`	`X`	`SPA`	`@0 Agente Venotrópico @5 78`
C07	`01`	`X`	`FRE`	`@0 Infection`
C07	`01`	`X`	`ENG`	`@0 Infection`
C07	`01`	`X`	`SPA`	`@0 Infección`
C07	`02`	`X`	`FRE`	`@0 Homme`
C07	`02`	`X`	`ENG`	`@0 Human`
C07	`02`	`X`	`SPA`	`@0 Hombre`
C07	`03`	`X`	`FRE`	`@0 Pathologie de la peau @5 37`
C07	`03`	`X`	`ENG`	`@0 Skin disease @5 37`
C07	`03`	`X`	`SPA`	`@0 Piel patología @5 37`
C07	`04`	`X`	`FRE`	`@0 Pathologie du tissu adipeux @5 38`
C07	`04`	`X`	`ENG`	`@0 Adipose tissue disorders @5 38`
C07	`04`	`X`	`SPA`	`@0 Tejido adiposo patología @5 38`
C07	`05`	`X`	`FRE`	`@0 Dermohypodermite @5 39`
C07	`05`	`X`	`ENG`	`@0 Dermatocellulitis @5 39`
C07	`05`	`X`	`SPA`	`@0 Dermatocelulitis @5 39`
C07	`06`	`X`	`FRE`	`@0 Pathologie de l'appareil circulatoire @5 40`
C07	`06`	`X`	`ENG`	`@0 Cardiovascular disease @5 40`
C07	`06`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 40`
C07	`07`	`X`	`FRE`	`@0 Pathologie des vaisseaux lymphatiques @5 41`
C07	`07`	`X`	`ENG`	`@0 Lymphatic vessel disease @5 41`
C07	`07`	`X`	`SPA`	`@0 Linfático patología @5 41`
C07	`08`	`X`	`FRE`	`@0 Flavonoïde @5 42`
C07	`08`	`X`	`ENG`	`@0 Flavonoid @5 42`
C07	`08`	`X`	`SPA`	`@0 Flavonoide @5 42`
C07	`09`	`X`	`FRE`	`@0 Polyphénol @5 43`
C07	`09`	`X`	`ENG`	`@0 Polyphenol @5 43`
C07	`09`	`X`	`SPA`	`@0 Polifenol @5 43`
C07	`10`	`X`	`FRE`	`@0 Phénols @2 FX @5 44`
C07	`10`	`X`	`ENG`	`@0 Phenols @2 FX @5 44`
C07	`10`	`X`	`SPA`	`@0 Fenoles @2 FX @5 44`
N21				`@1 052`

Format Inist (serveur)

NO :	PASCAL 08-0028056 INIST
ET :	Erysipelas and lymphedema
AU :	VAILLANT (Loïc)
AF :	Université François Rabelais/Tours/France (1 aut.)
DT :	Publication en série; Niveau analytique
SO :	Phlebolymphology; ISSN 1286-0107; France; Da. 2007; Vol. 14; No. 3; Pp. 120-124; Bibl. 19 ref.
LA :	Anglais
EA :	Erysipelas is a nonnecrotizing bacterial hypodermal cellulitis usually associated with streptococcal infection. It may be a mainly secondary complication of chronic lymphedema, and occurs in 20% to 30% of cases. The first presenting signs are sudden fever and shivering. The clinical feature is inflammatory plaque, which is often chronic and accompanied by fever. Inflammatory plaque is promoted by lymph stasis, and is marked by inflammatory episodes that often regress spontaneously. Erysipelas per se is mainly treated with antibiotics, and adjuvant therapies are not justified. The prevention of recurrence is primary. Since lymphedema is the first risk factor for recurrence, its treatment and risk of occurrence must be considered. This includes physiotherapy, well-adapted compression therapy, and avoidance of wounds.
CC :	002B24B04; 002B02F07; 002B12B01
FD :	Cellulite; Lymphoedème; Maladie héréditaire; Bactériose; Streptococcie; Erysipèle; Acquis; Congénital; Enfant; Diosmine; Glande mammaire; Circulation lymphatique; Complication; Chronique; Fièvre; Lymphe; Traitement; Antibiotique; Prévention; Facteur risque; Physiothérapie; Plaie; Veinotrope
FG :	Infection; Homme; Pathologie de la peau; Pathologie du tissu adipeux; Dermohypodermite; Pathologie de l'appareil circulatoire; Pathologie des vaisseaux lymphatiques; Flavonoïde; Polyphénol; Phénols
ED :	Cellulitis; Lymphedema; Genetic disease; Bacteriosis; Streptococcal infection; Erysipelas; Acquired; Congenital; Child; Diosmin; Mammary gland; Lymphatic circulation; Complication; Chronic; Fever; Lymph; Treatment; Antibiotic; Prevention; Risk factor; Physiotherapy; Wound; Venotropic agent
EG :	Infection; Human; Skin disease; Adipose tissue disorders; Dermatocellulitis; Cardiovascular disease; Lymphatic vessel disease; Flavonoid; Polyphenol; Phenols
SD :	Celulitis; Linfedema; Enfermedad hereditaria; Bacteriosis; Estreptococia; Erisipela; Adquirido; Congénito; Niño; Diosmina; Glándula mamaria; Circulación linfática; Complicación; Crónico; Fiebre; Linfa; Tratamiento; Antibiótico; Prevención; Factor riesgo; Fisioterapia; Herida; Agente Venotrópico
LO :	INIST-27793.354000162422740030
ID :	08-0028056

Links to Exploration step

Pascal:08-0028056

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Erysipelas and lymphedema</title>
<author><name sortKey="Vaillant, Loic" sort="Vaillant, Loic" uniqKey="Vaillant L" first="Loïc" last="Vaillant">Loïc Vaillant</name>
<affiliation><inist:fA14 i1="01"><s1>Université François Rabelais</s1>
<s2>Tours</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0028056</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 08-0028056 INIST</idno>
<idno type="RBID">Pascal:08-0028056</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000423</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Erysipelas and lymphedema</title>
<author><name sortKey="Vaillant, Loic" sort="Vaillant, Loic" uniqKey="Vaillant L" first="Loïc" last="Vaillant">Loïc Vaillant</name>
<affiliation><inist:fA14 i1="01"><s1>Université François Rabelais</s1>
<s2>Tours</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Phlebolymphology</title>
<idno type="ISSN">1286-0107</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Phlebolymphology</title>
<idno type="ISSN">1286-0107</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acquired</term>
<term>Antibiotic</term>
<term>Bacteriosis</term>
<term>Cellulitis</term>
<term>Child</term>
<term>Chronic</term>
<term>Complication</term>
<term>Congenital</term>
<term>Diosmin</term>
<term>Erysipelas</term>
<term>Fever</term>
<term>Genetic disease</term>
<term>Lymph</term>
<term>Lymphatic circulation</term>
<term>Lymphedema</term>
<term>Mammary gland</term>
<term>Physiotherapy</term>
<term>Prevention</term>
<term>Risk factor</term>
<term>Streptococcal infection</term>
<term>Treatment</term>
<term>Venotropic agent</term>
<term>Wound</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Cellulite</term>
<term>Lymphoedème</term>
<term>Maladie héréditaire</term>
<term>Bactériose</term>
<term>Streptococcie</term>
<term>Erysipèle</term>
<term>Acquis</term>
<term>Congénital</term>
<term>Enfant</term>
<term>Diosmine</term>
<term>Glande mammaire</term>
<term>Circulation lymphatique</term>
<term>Complication</term>
<term>Chronique</term>
<term>Fièvre</term>
<term>Lymphe</term>
<term>Traitement</term>
<term>Antibiotique</term>
<term>Prévention</term>
<term>Facteur risque</term>
<term>Physiothérapie</term>
<term>Plaie</term>
<term>Veinotrope</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Erysipelas is a nonnecrotizing bacterial hypodermal cellulitis usually associated with streptococcal infection. It may be a mainly secondary complication of chronic lymphedema, and occurs in 20% to 30% of cases. The first presenting signs are sudden fever and shivering. The clinical feature is inflammatory plaque, which is often chronic and accompanied by fever. Inflammatory plaque is promoted by lymph stasis, and is marked by inflammatory episodes that often regress spontaneously. Erysipelas per se is mainly treated with antibiotics, and adjuvant therapies are not justified. The prevention of recurrence is primary. Since lymphedema is the first risk factor for recurrence, its treatment and risk of occurrence must be considered. This includes physiotherapy, well-adapted compression therapy, and avoidance of wounds.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1286-0107</s0>
</fA01>
<fA05><s2>14</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Erysipelas and lymphedema</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>VAILLANT (Loïc)</s1>
</fA11>
<fA14 i1="01"><s1>Université François Rabelais</s1>
<s2>Tours</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA20><s1>120-124</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>27793</s2>
<s5>354000162422740030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>19 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0028056</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Phlebolymphology</s0>
</fA64>
<fA66 i1="01"><s0>FRA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Erysipelas is a nonnecrotizing bacterial hypodermal cellulitis usually associated with streptococcal infection. It may be a mainly secondary complication of chronic lymphedema, and occurs in 20% to 30% of cases. The first presenting signs are sudden fever and shivering. The clinical feature is inflammatory plaque, which is often chronic and accompanied by fever. Inflammatory plaque is promoted by lymph stasis, and is marked by inflammatory episodes that often regress spontaneously. Erysipelas per se is mainly treated with antibiotics, and adjuvant therapies are not justified. The prevention of recurrence is primary. Since lymphedema is the first risk factor for recurrence, its treatment and risk of occurrence must be considered. This includes physiotherapy, well-adapted compression therapy, and avoidance of wounds.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B24B04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02F07</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B12B01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Cellulite</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Cellulitis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Celulitis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lymphoedème</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Lymphedema</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Linfedema</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Maladie héréditaire</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Genetic disease</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Enfermedad hereditaria</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Bactériose</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Bacteriosis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Bacteriosis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Streptococcie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Streptococcal infection</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estreptococia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Erysipèle</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Erysipelas</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Erisipela</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Acquis</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Acquired</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Adquirido</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Congénital</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Congenital</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Congénito</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Enfant</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Child</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Niño</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Diosmine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Diosmin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Diosmina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Glande mammaire</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Mammary gland</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Glándula mamaria</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Circulation lymphatique</s0>
<s5>15</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Lymphatic circulation</s0>
<s5>15</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Circulación linfática</s0>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Complication</s0>
<s5>16</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Complication</s0>
<s5>16</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Complicación</s0>
<s5>16</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Chronique</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Chronic</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Crónico</s0>
<s5>17</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Fièvre</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Fever</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Fiebre</s0>
<s5>19</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Lymphe</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Lymph</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Linfa</s0>
<s5>20</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Traitement</s0>
<s5>21</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Treatment</s0>
<s5>21</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>21</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Antibiotique</s0>
<s5>22</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Antibiotic</s0>
<s5>22</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Antibiótico</s0>
<s5>22</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>Prévention</s0>
<s5>23</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG"><s0>Prevention</s0>
<s5>23</s5>
</fC03>
<fC03 i1="19" i2="X" l="SPA"><s0>Prevención</s0>
<s5>23</s5>
</fC03>
<fC03 i1="20" i2="X" l="FRE"><s0>Facteur risque</s0>
<s5>24</s5>
</fC03>
<fC03 i1="20" i2="X" l="ENG"><s0>Risk factor</s0>
<s5>24</s5>
</fC03>
<fC03 i1="20" i2="X" l="SPA"><s0>Factor riesgo</s0>
<s5>24</s5>
</fC03>
<fC03 i1="21" i2="X" l="FRE"><s0>Physiothérapie</s0>
<s5>25</s5>
</fC03>
<fC03 i1="21" i2="X" l="ENG"><s0>Physiotherapy</s0>
<s5>25</s5>
</fC03>
<fC03 i1="21" i2="X" l="SPA"><s0>Fisioterapia</s0>
<s5>25</s5>
</fC03>
<fC03 i1="22" i2="X" l="FRE"><s0>Plaie</s0>
<s5>26</s5>
</fC03>
<fC03 i1="22" i2="X" l="ENG"><s0>Wound</s0>
<s5>26</s5>
</fC03>
<fC03 i1="22" i2="X" l="SPA"><s0>Herida</s0>
<s5>26</s5>
</fC03>
<fC03 i1="23" i2="X" l="FRE"><s0>Veinotrope</s0>
<s5>78</s5>
</fC03>
<fC03 i1="23" i2="X" l="ENG"><s0>Venotropic agent</s0>
<s5>78</s5>
</fC03>
<fC03 i1="23" i2="X" l="SPA"><s0>Agente Venotrópico</s0>
<s5>78</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie de la peau</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Skin disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Piel patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du  tissu adipeux</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Adipose tissue disorders</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Tejido adiposo patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Dermohypodermite</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Dermatocellulitis</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Dermatocelulitis</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Pathologie des vaisseaux lymphatiques</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Lymphatic vessel disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Linfático patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Flavonoïde</s0>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Flavonoid</s0>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Flavonoide</s0>
<s5>42</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Polyphénol</s0>
<s5>43</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Polyphenol</s0>
<s5>43</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Polifenol</s0>
<s5>43</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Phénols</s0>
<s2>FX</s2>
<s5>44</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Phenols</s0>
<s2>FX</s2>
<s5>44</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Fenoles</s0>
<s2>FX</s2>
<s5>44</s5>
</fC07>
<fN21><s1>052</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 08-0028056 INIST</NO>
<ET>Erysipelas and lymphedema</ET>
<AU>VAILLANT (Loïc)</AU>
<AF>Université François Rabelais/Tours/France (1 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Phlebolymphology; ISSN 1286-0107; France; Da. 2007; Vol. 14; No. 3; Pp. 120-124; Bibl. 19 ref.</SO>
<LA>Anglais</LA>
<EA>Erysipelas is a nonnecrotizing bacterial hypodermal cellulitis usually associated with streptococcal infection. It may be a mainly secondary complication of chronic lymphedema, and occurs in 20% to 30% of cases. The first presenting signs are sudden fever and shivering. The clinical feature is inflammatory plaque, which is often chronic and accompanied by fever. Inflammatory plaque is promoted by lymph stasis, and is marked by inflammatory episodes that often regress spontaneously. Erysipelas per se is mainly treated with antibiotics, and adjuvant therapies are not justified. The prevention of recurrence is primary. Since lymphedema is the first risk factor for recurrence, its treatment and risk of occurrence must be considered. This includes physiotherapy, well-adapted compression therapy, and avoidance of wounds.</EA>
<CC>002B24B04; 002B02F07; 002B12B01</CC>
<FD>Cellulite; Lymphoedème; Maladie héréditaire; Bactériose; Streptococcie; Erysipèle; Acquis; Congénital; Enfant; Diosmine; Glande mammaire; Circulation lymphatique; Complication; Chronique; Fièvre; Lymphe; Traitement; Antibiotique; Prévention; Facteur risque; Physiothérapie; Plaie; Veinotrope</FD>
<FG>Infection; Homme; Pathologie de la peau; Pathologie du  tissu adipeux; Dermohypodermite; Pathologie de l'appareil circulatoire; Pathologie des vaisseaux lymphatiques; Flavonoïde; Polyphénol; Phénols</FG>
<ED>Cellulitis; Lymphedema; Genetic disease; Bacteriosis; Streptococcal infection; Erysipelas; Acquired; Congenital; Child; Diosmin; Mammary gland; Lymphatic circulation; Complication; Chronic; Fever; Lymph; Treatment; Antibiotic; Prevention; Risk factor; Physiotherapy; Wound; Venotropic agent</ED>
<EG>Infection; Human; Skin disease; Adipose tissue disorders; Dermatocellulitis; Cardiovascular disease; Lymphatic vessel disease; Flavonoid; Polyphenol; Phenols</EG>
<SD>Celulitis; Linfedema; Enfermedad hereditaria; Bacteriosis; Estreptococia; Erisipela; Adquirido; Congénito; Niño; Diosmina; Glándula mamaria; Circulación linfática; Complicación; Crónico; Fiebre; Linfa; Tratamiento; Antibiótico; Prevención; Factor riesgo; Fisioterapia; Herida; Agente Venotrópico</SD>
<LO>INIST-27793.354000162422740030</LO>
<ID>08-0028056</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000423 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000423 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0028056
   |texte=   Erysipelas and lymphedema
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Erysipelas and lymphedema

Erysipelas and lymphedema

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri